GNQ INSILICO – COMPETITIVE ADVANTAGE
Where Causal Biology Meets Clinical Precision
GNQ’s pathway-driven platform doesn’t just predict – it also explains. By modeling the biological mechanisms that determine patient outcomes, we deliver what the new regulatory era demands: one definitive trial, designed right from the start.
GNQ INSILICO – COMPETITIVE ADVANTAGE
Improved Prediction Accuracy
vs. traditional ML/Deep Learning methods
Trial Cost Reduction
through stratified patient selection pre-trial
Systems Biology
in GNQ’s proprietary biological knowledge graph
Early Resistance Detection
before clinical manifestation
SIDE-BY-SIDE COMPARISON
| TRADITIONAL APPROACHES Correlation-based AI / Standard ML | GNQ INSILICO PLATFORM DAP – PATHWAY DRIVEN – CAUSAL AI | |
|---|---|---|
| Reasoning Method | Statistical pattern matching on historical data → black box, no biological basis | Causal inference through millions of curated pathway relationships → mechanistic, explainable predictions |
| Trial Design | Post-hoc subgroup discovery (18+ months) → population averages, no stratification | Insilico patient simulations before first enrollment → stratified Phase 1 arms ab initio |
| Resistance Prediction | Detected at clinical progression (imaging at 12 weeks) → reactive, too late to redirect | Predicted 3–6 months before clinical manifestation → proactive therapy switches at week 4–8 |
| FDA Alignment (2026) | Requires two trials to compensate for lack of mechanistic support → high cost, long timelines | Generates the “complete biological story” FDA now requires for 1-trial approval → biomarker + causal + pathway evidence |
| Patient Populations | Requires large, homogeneous cohorts to find signal → excludes rare genotypes, rare diseases | Works with small, genetically diverse cohorts via pathway biology → viable for rare disease, pediatric, rare cancers |
| Knowledge Source | Dependent on historical training data volume → fails in novel or data-sparse domains | 20M+ causal links connecting pathways, genes, enzymes, hormones, conditions, therapies… → Biological reasoning independent of data volume |
| Regulatory Package | Statistical output only – limited mechanistic narrative → difficult to construct dossier FDA trusts | Mechanistic narrative + biomarker trajectory + pathway causality → built for FDA, SaMD and 510(k) submissions |
THREE CORE DIFFERENTIATORS – 01
Causal Biology, Not Correlation
GNQ’s Drug Assessment Platform models biological mechanisms through graph neural ODEs and neural stochastic differential equations – not pattern matching. The platform tells you why a therapy will work for a specific patient’s molecular profile, not just that it might.
02
Insilico Trials Before Real Patients
GNQ’s digital twin engine – validated on thousands of real patients and synthetic patients – identifies responder populations before Phase 1 enrollment begins. Design smarter, smaller, faster trials with the stratification built in from day one.
03
The Complete Biological Story FDA Demands
The FDA’s new one-trial standard requires more than statistics – it requires “a complete biological story.” GNQ’s integrated outputs of pathway scores, biomarker trajectories, and causal explanations are precisely the evidence package that satisfies the new evidentiary standard.
REGULATORY TAILWIND
GNQ Platform Was Built for the Era the FDA Just Declared
Biomarker-Driven Evidence
FDA now accepts biomarker trajectories as core confirmatory evidence. GNQ predicts M-protein, serum free light chains, and pathway scores as real-time biomarkers – exactly the package FDA describes.
Smaller, Stratified Trials
FDA explicitly rewards patient stratification that reduces false-positive risk. GNQ identifies responder subgroups pre-enrollment, enabling Phase 2 trials with 50% fewer patients and cleaner signals.
Post-Market Real-World Evidence
The new one-trial model shifts burden to post- approval RWE. GNQ’s continuous monitoring architecture – built on FHIR + federated learning – generates registry-grade evidence automatically at scale.
“In 2026, there are powerful alternative ways to feel assured that our products help people live longer or better than requiring manufacturers to test them yet again.”
FDA Commissioner Makary & CBER Director Prasad, NEJM, Feb 2026